VIVXF News and Press, Avivagen From 03/21/24

X4 Pharmaceuticals Inc. (XFOR) is expected to report $-0.15 for Q4 2023 Li Ning Co., Ltd. ADR (LNNGY) is expected to report for Q4 2023 Xos Inc. (XOS) is expected to report $-2.4 for Q4 2023 PainReform Ltd. (PRFX) is expected to report for quarter end 2023-12-31 Muenchener Rueckve...

Regenicin Inc (RGIN) is expected to report for quarter end 2023-06-30 Grasim Industries Ltd. ADR (GRSXY) is expected to report for quarter end 2023-06-30 Mitsubishi Heavy Industries Ltd. (MHVYF) is expected to report for Q1 2024 Japan Tobacco Inc. ADR (JAPAY) is expected to report $0....

World Copper (WCUFF) is expected to report $-0.01 for Q2 2023 GlassBridge Enterprises Inc (GLAE) is expected to report for quarter end 2023-06-30 Paladin Energy Ltd (PALAF) is expected to report for Q4 2023 Andritz AG ADR (ADRZY) is expected to report for Q2 2023 Cincinnati Bancor...

2023-07-24 10:56:12 ET Avivagen Inc ( TSXV: VIV:CA ) on Monday announced two orders for OxC-beta. The company said one order, for 500kgs, is with a new customer for use within the sow market, while the second order, for 600kgs, involves 100kgs for immediate delivery and an add...

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, the...

2023-03-17 08:32:08 ET Avivagen press release ( OTCPK:VIVXF ): Q1 GAAP EPS of -C$0.01. Revenue of C$0.07M (-74.1% Y/Y). For further details see: Avivagen GAAP EPS of -$0.01, revenue of $0.07M

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health ...

-Publication showcases the cumulative understanding to-date of Avivagen’s product from both a scientific and real world application perspective -Product’s value and safety has been shown through use in many settings, under differing conditions and in millions of animals ...

Avivagen Inc. (TSXV:VIV) (“ Avivagen ” or the “ Company ”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting...

Avivagen press release ( OTCQB:VIVXF ): Q3 Comprehensive loss of C$1.90M Revenue of C$48.61K (-94.5% Y/Y). For further details see: Avivagen reports Q3 results